Toward this end, a recent phase 1/2 clinical trial showed an improved clinical outcome defined by an overall response rate of 45.8% in patients with drug-resistant, locally advanced breast cancer (LABC) and metaplastic TNBC who received the NOS inhibitor L-NMMA and low-dose aspirin combined with taxane (21). This evidence concerns the gene NOS2 and breast cancer.